Open Orphan Share Discussion Threads

[inaminute] 19/4/2021 10:55

The uncertainty this morning about whether or not we are involved has not helped. Need a statement to clarify (hopefully confirm) from the marketing dept.

[squintyflinty] 19/4/2021 10:48

Yes and I've added on the weakness. I can also see this share hitting a £1

[glasswala] 19/4/2021 10:37

It was up before the market heard the news and since then has dropped 20% so my assertion is only on the effect of the news to share price. I am a long term holder hoping to make a good amount qhen this hits 1pound

[kpe] 19/4/2021 10:34

Just received details of the demerger. 1 share in the new company for each oo share owned. Lock in for 9 months.

[owenski] 19/4/2021 10:26

BB has gone a bit quiet lately, always a good sign, it means the noisy tuppeny hapenny traders are leaving. Meanwhile, for investors, the business investment case remains the same.

[gf123] 19/4/2021 10:22

Up around 40% in a month. Yes very poor

[discojames] 19/4/2021 10:21

I dont think anyone wants a low-ball buyout offer now, we want all the spin offs done and DIM subscriptions flowing in before the buyout for the rest of it.

[glasswala] 19/4/2021 10:18

The market reaction to the demerger of non core assets into new company has been pooely received.I think the market was hoping that a buyer would be sniffing around a whole of Orph.There should be more news this month as per CF 's last presentation.

[lauders] 19/4/2021 09:08

Averaged down after buying a bit too high earlier this month. So now I shall keep an eye on this BB a bit more regularly.

Extrader - Your links activated (just change first letter to upper case ;-])

[extrader] 19/4/2021 08:45

Thanks, Trader_3.

Interesting to see amongst the other attendees
Meta Roestenberg
hxxps://www.lumc.nl/org/parasitologie/medewerkers/metaroestenberg

and Chad Porter
hxxps://www.researchgate.net/profile/Chad-Porter

HTH

[trader_3] 19/4/2021 08:27

‘The first phase of the trial, led by the University of Oxford, will test the dose of virus required to reinfect through nasal administration. The second phase will record the immune response, including immunity gained through previous infections. Vaccines will not be used at these two stages.

Volunteers will be tracked for one year. Professor Helen said that they will be paid about 5,000 pounds (about 4,5058.5 yuan) during their isolation and tracking. Oxford University’s partners include hVIVO Services, a drug testing company that has experience in challenging trials and also participated in research at Imperial College.’



+

Hvivo historical link to Dr Helen Mc Shane, including meeting with: Dr Andrew Catchpole; Adrian Wildfire; Wellcome Trust; Prof Andrew Pollard & Dr Peter Openshaw:-

Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020.

[inaminute] 19/4/2021 07:58

Eskers is suggesting this is funded by the Wellcome Trust and will be run inside Oxford University Hospitals.

[inaminute] 19/4/2021 07:43

If so then would expect an update from ORPH via marketing. Forthcoming results should also indicate how the govt contract income will hit the p&l

[gregb] 19/4/2021 07:35

Perhaps part of the original Gov contract. They did book 3 studies with us in the 1st instance so no RNS required.

[inaminute] 19/4/2021 07:19

Sky post said the people will be cared for by researchers at a hospital. Unless a private hospital I cannot see the Govt awarding us earlier contracts and giving this to someone else at an NHS facility.

[timberwolf3] 19/4/2021 07:08

Thanks marvelman, that's got Orph's fingerprints all over it.

[yasyas1] 18/4/2021 22:22

Cannot access unfortunately

[pogue] 18/4/2021 20:13

Extrader
Eskers has posted a picture of the paper copy of the article on the thread.

[extrader] 18/4/2021 18:55

The article is behind a paywall, could Some Kind Person post the 'bones', pls ?

TIA

[1gw] 18/4/2021 10:35

Interesting. To value the spin-out from that (£20m+ could be raised), we need to know how much equity would be issued in the IPO. If it's 10% (ie equity offered is 10% of the enlarged share capital) then that would value it at £200m, with Orph's remaining equity valued at £180m. If it's more than 10% offered (to raise the same £20m) then that would reduce the values accordingly.

[natolly] 18/4/2021 09:47

All good news, GLA

[1gw] 16/4/2021 18:17

Don't think so, as if that were the case it would be flagged with yesterday's date on the London South East site, and would appear at the start of the day on the advfn streaming feed.

[donaferentes] 16/4/2021 18:12

Conceivably a late reported worked buy from yesterday pm?